News & Updates

Use of APCC in an elderly AHA patient requiring invasive procedures

03 Feb 2025 by

An 81-year-old female presented to a private hospital with painful right upper arm swelling and bruising in August 2023. There was no history of trauma or contusion other than a minor sprain 2 weeks prior to presentation. There was also no family history of bleeding tendency. The patient had multiple comorbidities: hypertension, hyperlipidaemia, type 2 diabetes (T2D), overweight (body weight, 60 kg; BMI, 25 kg/m²), osteoarthritis of both knees, and vitamin B12 deficiency.

Use of APCC in an elderly AHA patient requiring invasive procedures

03 Feb 2025

CTAD 2024: Origin of lecanemab and real-world experience in its use

20 Jan 2025 by

At the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference held in Madrid, Spain, researchers from the US and Japan shared real-world clinical experience with lecanemab, the first approved disease-modifying treatment for early Alzheimer’s disease (AD). Professor Lars Lannfelt of Uppsala University, Sweden, who received the CTAD Lifetime Achievement Award in recognition of his pioneering work that led to the development of the monoclonal antibody (mAb) drug, described the origins of his ground-breaking discovery.

CTAD 2024: Origin of lecanemab and real-world experience in its use

20 Jan 2025

Early SGLT2i initiation stalls CKD progression, may delay dialysis

20 Jan 2025 by

Empagliflozin’s recently approved chronic kidney disease (CKD) indication expands the spectrum of patients with cardio-renal-metabolic (CRM) conditions who may benefit from treatment. At the 26^th Diabetes and Cardiovascular Risk Factors – East Meets West Symposium, Dr Ted Wu, Director of the Diabetes Centre, Royal Prince Alfred Hospital in Sydney, Australia, and Honorary Professor, Shijiazhuang Diabetes Hospital, Hebei, China, highlighted empagliflozin’s benefits in CKD, type 2 diabetes (T2D) and heart failure (HF), and discussed how early initiation of empagliflozin may stall CKD progression and delay dialysis.

Early SGLT2i initiation stalls CKD progression, may delay dialysis

20 Jan 2025

T-DXd in HER2-low mBC: From molecular mechanism to clinical evidence and beyond

20 Jan 2025 by

HER2-low metastatic breast cancer (mBC) is a heterogeneous disease with diverse clinicopathological characteristics and limited later-line treatment options. During an industry-sponsored symposium organized by the Hong Kong Breast Oncology Group, Dr Erika Hamilton of Sarah Cannon Research Institute, Tennessee, US, discussed molecular mechanism and clinical evidence on the use of trastuzumab deruxtecan (T-DXd; Enhertu^®, Daiichi Sankyo & AstraZeneca) in pretreated HER2-low mBC.

T-DXd in HER2-low mBC: From molecular mechanism to clinical evidence and beyond

20 Jan 2025

[Infographics] ARNI: First-line RASI in 4-pillar GDMT for HFrEF

15 Jan 2025

2024 American College of Cardiology’s Expert Consensus Decision Pathway for Treatment of Heart Failure with Reduced Ejection Fraction (HFrEF), the most recent international guidance on HFrEF treatment, recommends angiotensin receptor/neprilysin inhibitor (ARNI; ie, sacubitril/valsartan) as the preferred renin-angiotensin system inhibitor (RASI), which should be used as first-line therapy whenever possible. Emphasis is placed on initiating and titrating guideline-directed medical therapy (GDMT) early and rapidly. Here is why and how.

[Infographics] ARNI: First-line RASI in 4-pillar GDMT for HFrEF

15 Jan 2025

Treatment decisions in post-neoadjuvant HER2-positive early breast cancer

13 Jan 2025 by

Patients HER2-positive (HER2+) breast cancer (BC) who achieve pathological complete response (pCR) have significantly better event-free survival (EFS), yet pCR cannot overcome the prognostic impact of baseline tumour size and nodal status. At an industry-sponsored symposium, Professor Michael Untch of Obstetrics and Gynaecology Department of Helios Hospital in Berlin, Germany, discussed considerations behind treatment decisions in post-neoadjuvant HER2+ early BC and data supporting the use of neratinib, an irreversible, small-molecule pan-HER tyrosine kinase inhibitor (TKI), in this setting.

Treatment decisions in post-neoadjuvant HER2-positive early breast cancer

13 Jan 2025

Use of maintenance immunotherapy as bladder-preserving therapy in node-positive muscle-invasive urothelial carcinoma

10 Jan 2025 by

A 45-year-old nonsmoking, non-drinking Chinese male with good past health presented in 2019 with haematuria. He was initially diagnosed with non–muscle invasive urothelial carcinoma (UC) of the bladder. Transurethral resection of bladder tumour (TURBT) was performed in June and August 2019, followed by three courses of intravesical Bacillus Calmette-Guerin between September 2019 and May 2020. His baseline Eastern Cooperative Oncology Group Performance Status (ECOG PS) was 1.

Use of maintenance immunotherapy as bladder-preserving therapy in node-positive muscle-invasive urothelial carcinoma

10 Jan 2025

Addressing unmet needs in generalized pustular psoriasis: Real-world insights

07 Jan 2025

As a rare and heterogeneous autoinflammatory skin disease, generalized pustular psoriasis (GPP) currently lacks clear and consistent management guidelines, presenting treatment challenges particularly for patients experiencing recurrent flares. This article highlights global GPP data presented at the European Academy of Dermatology and Venereology (EADV) Congress 2024 and reports recent case series of Chinese and Italian patients with GPP flares treated with spesolimab, an interleukin (IL)-36 receptor antagonist.

Addressing unmet needs in generalized pustular psoriasis: Real-world insights

07 Jan 2025

Early initiation of extended adjuvant therapy in a high-risk patient with early-stage HER2-positive breast cancer

06 Jan 2025 by

A 35-year-old premenopausal female who was otherwise healthy presented in July 2022 with a mass in the left breast and palpable lymph nodes (LN) in the left axillary area. She was asymptomatic, and her Eastern Cooperative Oncology Group (ECOG) performance status (PS) score was 0–1.

Early initiation of extended adjuvant therapy in a high-risk patient with early-stage HER2-positive breast cancer

06 Jan 2025

A high-risk patient with early-stage HER2-positive breast cancer treated with extended adjuvant therapy

06 Jan 2025 by

A 48-year-old premenopausal female presented in July 2021 with a self-detected nodule in her left breast, which she had noticed 1 week ago. Upon physical examination, a 2 cm mass in the left breast and a 2 cm lymph node (LN) in the left axilla were palpable. Further diagnostic workup revealed an irregular-shaped mass measuring 18 x 12 mm with lobulated edges and an enlarged LN of 24 x 13.9 mm in the left axilla, without distant metastasis. Biopsy of the breast mass showed invasive carcinoma that was HER2-positive, oestrogen receptor (ER)–negative and progesterone receptor (PR)–negative, with a Ki-67 level of 50 percent. The patient was diagnosed with HER2-positive breast cancer (BC; cT1N1M0).

A high-risk patient with early-stage HER2-positive breast cancer treated with extended adjuvant therapy

06 Jan 2025

News & Updates

Filter by Specialty:

Specialty:

Use of APCC in an elderly AHA patient requiring invasive procedures

Use of APCC in an elderly AHA patient requiring invasive procedures

CTAD 2024: Origin of lecanemab and real-world experience in its use

CTAD 2024: Origin of lecanemab and real-world experience in its use

Early SGLT2i initiation stalls CKD progression, may delay dialysis

Early SGLT2i initiation stalls CKD progression, may delay dialysis

T-DXd in HER2-low mBC: From molecular mechanism to clinical evidence and beyond

T-DXd in HER2-low mBC: From molecular mechanism to clinical evidence and beyond

[Infographics] ARNI: First-line RASI in 4-pillar GDMT for HFrEF

[Infographics] ARNI: First-line RASI in 4-pillar GDMT for HFrEF

Treatment decisions in post-neoadjuvant HER2-positive early breast cancer

Treatment decisions in post-neoadjuvant HER2-positive early breast cancer

Use of maintenance immunotherapy as bladder-preserving therapy in node-positive muscle-invasive urothelial carcinoma

Use of maintenance immunotherapy as bladder-preserving therapy in node-positive muscle-invasive urothelial carcinoma

Addressing unmet needs in generalized pustular psoriasis: Real-world insights

Addressing unmet needs in generalized pustular psoriasis: Real-world insights

Early initiation of extended adjuvant therapy in a high-risk patient with early-stage HER2-positive breast cancer

Early initiation of extended adjuvant therapy in a high-risk patient with early-stage HER2-positive breast cancer

A high-risk patient with early-stage HER2-positive breast cancer treated with extended adjuvant therapy

A high-risk patient with early-stage HER2-positive breast cancer treated with extended adjuvant therapy